(Q38033673)

27 August 2017

title

European consensus document on mast cell tumours in dogs and cats (English)

1 reference

27 August 2017

0 references

1 reference

27 August 2017

F Ponce

0 references

Johannes Hirschberger

J Hirschberger

0 references

P Buracco

0 references

L Blackwood

1 reference

27 August 2017

S Murphy

1 reference

27 August 2017

J P De Vos

1 reference

27 August 2017

P De Fornel-Thibaud

1 reference

27 August 2017

M Kessler

1 reference

27 August 2017

K Savary-Bataille

1 reference

27 August 2017

D J Argyle

1 reference

27 August 2017

language of work or name

1 reference

1 September 2012

1 reference

Veterinary and Comparative Oncology

27 August 2017

published in

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

e1-e29

1 reference

Mast cell mediators in allergic inflammation and mastocytosis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Mast cell tumors in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Evaluation of risk and clinical outcome of mast cell tumours in pug dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Advances in the diagnosis and management of cutaneous mast cell tumours in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Mast cell tumors of the gastrointestinal tract in 39 dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Visceral mast cell tumors in dogs: 10 cases (1982-1997).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Principles of treatment for mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Radiation therapy for incompletely resected canine mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Tolerance of cutaneous or mucosal flaps placed into a radiation therapy field in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Results of radiation therapy in 19 dogs with cutaneous mast cell tumor and regional lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Treatment of canine mast cell tumours with prednisolone and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Dose-escalating vinblastine for the treatment of canine mast cell tumour.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Prospective Randomized Clinical Trial Assessing the Efficacy of Denamarin for Prevention of CCNU‐Induced Hepatopathy in Tumor‐Bearing Dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Masitinib is safe and effective for the treatment of canine mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Deionised water and mast cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Pilot study of intraregional deionised water adjunct therapy for mast cell tumours in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Photodynamic Therapy of Spontaneous Cancers in Felines, Canines, and Snakes With Chloro-aluminium Sulfonated Phthalocyanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Veterinary photodynamic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Fluorescence detection of a new photosensitizer, PAD-S31, in tumour tissues and its use as a photodynamic treatment for skin tumours in dogs and a cat: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Histopathology and biologic behavior of pleomorphic cutaneous mast cell tumors in fifteen cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Prognostic value of histologic and immunohistochemical features in feline cutaneous mast cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Evaluation of strontium 90 irradiation in treatment of cutaneous mast cell tumors in cats: 35 cases (1992-2002).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

Safety of masitinib mesylate in healthy cats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1476-5829.2012.00341.X

10.1111/J.1476-5829.2012.00341.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference